Editas Medicine Inc (NASDAQ:EDIT) CFO Andrew A. F. Hack sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $38.06, for a total value of $1,522,400.00. Following the completion of the sale, the chief financial officer now owns 6,000 shares of the company’s stock, valued at approximately $228,360. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Editas Medicine Inc (EDIT) traded up $0.84 during trading hours on Tuesday, reaching $38.14. The company had a trading volume of 1,075,669 shares, compared to its average volume of 1,770,474. The company has a market cap of $1,782.56, a P/E ratio of -12.80 and a beta of 3.68. Editas Medicine Inc has a one year low of $13.12 and a one year high of $45.02. The company has a quick ratio of 9.05, a current ratio of 9.05 and a debt-to-equity ratio of 0.16.
Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Tuesday, March 6th. The company reported ($0.84) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.09). The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $4.25 million. Editas Medicine had a negative return on equity of 61.92% and a negative net margin of 876.49%. Editas Medicine’s revenue for the quarter was up 311.1% on a year-over-year basis. During the same period last year, the firm earned ($1.10) earnings per share. research analysts anticipate that Editas Medicine Inc will post -3.3 EPS for the current fiscal year.
A number of analysts recently weighed in on the company. BidaskClub downgraded Editas Medicine from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Zacks Investment Research upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. Barclays boosted their target price on Editas Medicine from $28.00 to $46.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 7th. SunTrust Banks upgraded Editas Medicine from a “hold” rating to a “buy” rating and boosted their target price for the stock from $17.00 to $45.00 in a research report on Tuesday, January 23rd. Finally, Cann restated a “hold” rating on shares of Editas Medicine in a research report on Friday, February 16th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Editas Medicine presently has a consensus rating of “Hold” and an average price target of $40.02.
A number of institutional investors have recently made changes to their positions in the business. Slow Capital Inc. purchased a new position in Editas Medicine in the 4th quarter worth approximately $391,000. MetLife Investment Advisors LLC purchased a new position in Editas Medicine in the 4th quarter worth approximately $509,000. Glenmede Trust Co. NA purchased a new position in Editas Medicine in the 4th quarter worth approximately $153,000. Financial Advocates Investment Management purchased a new position in Editas Medicine in the 4th quarter worth approximately $319,000. Finally, Millennium Management LLC increased its stake in Editas Medicine by 13.2% in the 4th quarter. Millennium Management LLC now owns 422,757 shares of the company’s stock worth $12,991,000 after purchasing an additional 49,336 shares during the period. 64.49% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Editas Medicine Inc (EDIT) CFO Andrew A. F. Hack Sells 40,000 Shares” was published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2018/03/20/editas-medicine-inc-edit-cfo-andrew-a-f-hack-sells-40000-shares.html.
Editas Medicine Company Profile
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.